Tirzepatide on TikTok: separating week-3 wins from real clinical data

What did @erikachristinemaldonado actually say?

She's three weeks into tirzepatide, took her third shot the day before filming, and is eating McDonald's fries. Her main claims: no nausea so far, cravings have decreased, she's been naturally delaying meals until 1-3 PM, she's down one or two pounds, and "most results don't start to show up until like four weeks later." That last one is the claim worth examining most closely.

She's not making dramatic promises. No specific weight loss goals, no dosing advice, no medical claims about disease treatment. For a 172K-view TikTok about a GLP-1 medication, this is relatively measured content. She credits a medical provider, @shemedconsult, which is at least better than the videos where people are self-titrating based on comment sections.

Does the science back this up?

The hunger suppression piece is well-supported. The four-week results timeline is a rough approximation that holds up in broad strokes, though the real picture is more complicated than that.

Tirzepatide acts on both GIP and GLP-1 receptors, which together reduce gastric emptying and appetite signaling. In the SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine), participants on the highest dose (15 mg) lost a mean of 20.9% of body weight over 72 weeks. But meaningful weight loss, defined as 5% or more, took months, not weeks. That said, appetite changes can begin earlier. A 2023 paper by Dahl et al. in Obesity Reviews noted that subjective appetite reduction with dual GIP/GLP-1 agonists often precedes measurable weight change, which aligns with her experience of eating later in the day without feeling hungry.

Her observation about skipping breakfast and not eating until early afternoon is consistent with what researchers call reduced meal initiation, a documented behavioral effect of GLP-1 class drugs. It is not the same as fasting, but the outcome can look similar on the surface.

What did they get wrong (or right)?

The four-week timeline claim is partly right but also a bit of a myth that circulates heavily in GLP-1 communities online. Here is the nuance she missed.

Early GLP-1 effects on appetite can appear within days to the first couple of weeks, not at some clean four-week threshold. The SURMOUNT-1 data showed statistically significant weight differences from placebo as early as week 4, but that reflects study measurement intervals, not a biological switch that flips at day 28. Some people notice appetite changes in week one. Others, especially at lower starting doses, notice very little for the first month. The four-week figure has been repeated so many times in patient communities that it functions more like folklore than pharmacokinetics at this point.

What she got right: the one to two pound loss at three weeks is realistic and not a red flag. Early weight changes on tirzepatide are often modest and partly water weight. The SURMOUNT-1 curve shows slow early loss that accelerates over time. Her expectation-setting here is actually healthier than what a lot of GLP-1 content pushes.

She also got the nausea piece right by omission. Not everyone experiences nausea, and its absence does not mean the medication is not working. That misconception sends a lot of people toward dose escalation they do not need.

What should you actually know?

If you are starting tirzepatide, the four-week "results" benchmark floating around social media is not a clinical standard. It is a community expectation, and treating it as a deadline can push people toward unnecessary dose increases or discouragement.

The clinical reality is that tirzepatide's weight loss effect is dose-dependent and cumulative. The SURMOUNT-1 trial used a gradual titration schedule, starting at 2.5 mg and increasing every four weeks. Full therapeutic doses (10-15 mg) were not reached until weeks 16-20 for many participants. Expecting significant body composition changes at week four on a starting dose is optimistic at best.

Reduced appetite and delayed meal timing, what she is describing, are meaningful early signals. A 2022 analysis by Rosenstock et al. in The Lancet found that GIP/GLP-1 dual agonism produces appetite suppression that is meaningfully stronger than GLP-1 alone, which may explain why some tirzepatide users report more pronounced hunger reduction than those on semaglutide. But individual response varies considerably, and the absence of dramatic early symptoms is not a reason to escalate dose or switch medications.

One more thing: eating McDonald's fries while on tirzepatide is not medically problematic. The medication does not require a specific diet to function. But the reduced appetite effect can mask how little someone is eating, which makes nutrition quality more important, not less. Getting adequate protein and micronutrients on lower caloric intake is a real clinical consideration that GLP-1 content rarely addresses.